Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 33% Improvement Relative Risk Mortality (b) 27% Mortality (c) 25% Mortality (d) 12% c19early.org/d Loucera et al. Vitamin D for COVID-19 Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? PSM retrospective 1,604 patients in Spain Lower mortality with vitamin D (p=0.0088) Loucera et al., Scientific Reports, doi:10.1038/s41598-021-02701-5 Favors vitamin D Favors control
Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients
Loucera et al., Scientific Reports, doi:10.1038/s41598-021-02701-5 (date from earlier preprint)
Loucera et al., Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective.., Scientific Reports, doi:10.1038/s41598-021-02701-5 (date from earlier preprint)
Apr 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 15,968 hospitalized patients in Spain showing a significant reduction in mortality associated with the prescription of vitamin D, especially calcifediol, within 15-30 days prior to hospitalization.
risk of death, 33.0% lower, HR 0.67, p = 0.009, treatment 374, control 374, calcifediol, <15 days before hospitalization, Cox model with inverse propensity weighting.
risk of death, 27.0% lower, HR 0.73, p = 0.02, treatment 439, control 439, calcifediol, <30 days before hospitalization, Cox model with inverse propensity weighting.
risk of death, 25.0% lower, HR 0.75, p = 0.005, treatment 570, control 570, cholecalciferol, <15 days before hospitalization, Cox model with inverse propensity weighting.
risk of death, 12.0% lower, HR 0.88, p = 0.11, treatment 802, control 802, cholecalciferol, <30 days before hospitalization, Cox model with inverse propensity weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Loucera et al., 29 Apr 2021, retrospective, propensity score matching, Spain, peer-reviewed, 11 authors, dosage varies (calcifediol).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: www.nature.com/scientificreports OPEN Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID‑19 in a retrospective cohort of hospitalized Andalusian patients Carlos Loucera1,2, María Peña‑Chilet1,2,3, Marina Esteban‑Medina1,2, Dolores Muñoyerro‑Muñiz4, Román Villegas4, Jose Lopez‑Miranda5,6, Jesus Rodriguez‑Baño2,7,8, Isaac Túnez9,10,11,12, Roger Bouillon13, Joaquin Dopazo1,2,3,14* & Jose Manuel Quesada Gomez10,15* COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. We present a survival study on a retrospective cohort of 15,968 patients, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Based on a central registry of electronic health records (the Andalusian Population Health Database, BPS), prescription of vitamin D or its metabolites within 15–30 days before hospitalization were recorded. The effect of prescription of vitamin D (metabolites) for other indication previous to the hospitalization was studied with respect to patient survival. Kaplan–Meier survival curves and hazard ratios support an association between prescription of these metabolites and patient survival. Such association was stronger for calcifediol (Hazard Ratio, HR = 0.67, with 95% confidence interval, CI, of [0.50–0.91]) than for cholecalciferol (HR = 0.75, with 95% CI of [0.61–0.91]), when prescribed 15 days prior hospitalization. Although the relation is maintained, there is a general decrease of this effect when a longer period of 30 days prior hospitalization is considered (calcifediol HR = 0.73, with 95% CI [0.57–0.95] and cholecalciferol HR = 0.88, with 95% CI [0.75, 1.03]), suggesting that association was stronger when the prescription was closer to the hospitalization. 1 Clinical Bioinformatics Area, Fundación Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio, 41013 Seville, Spain. 2Institute of Biomedicine of Seville (IBIS), Hospital Virgen del Rocio, 41013 Seville, Spain. 3Bioinformatics in Rare Diseases (BiER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocio, 41013 Seville, Spain. 4Subdirección Técnica Asesora de Gestión de la Información, Servicio Andaluz de Salud, Seville, Spain. 5Internal Medicine Department, IMIBIC/Reina Sofia University Hospital/University of Cordoba, 14004 Córdoba, Spain. 6CIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. 7Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen Macarena, Seville, Spain. 8Departamento de Medicina, Universidad de Sevilla, Seville, Spain. 9Departamento de Bioquimica y Biología Molecular, Facultad de Medicina y Enfermería, Universidad de Córdoba, Córdoba, Spain. 10Instituto Maimónides de Investigacion Biomédica de Córdoba (IMIBIC), 14004 Córdoba, Spain. 11G. Técnico de Expertos de Andalucía para Estudios de Suplementos e Intervención Nutricional Frente a Covid-19, SGIDIS, Consejería de Salud y Familias, Junta de Andalucia, Seville, Spain. 12Secretaria General de Investigación, Desarrollo e Innovación en Salud, Consejería de Salud y Familias de la Junta de Andalucía, Seville, Spain. 13Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism,..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit